



Neuren raises \$2 million through underwritten Share Purchase Plan

Tuesday, 30 September 2008: Neuren Pharmaceuticals Limited (ASX: NEU) today announced that it had received applications for 7,350,000 ordinary shares amounting to approximately A\$588,000 under its Share Purchase Plan (SPP) which closed on 16 September 2008. As the SPP was underwritten by Taylor Collison up to A\$2.05 million, the underwriter and sub-underwriters subscribed for 18,275,000 ordinary shares amounting to A\$1,462,000.

The Company allotted the new shares today. Transaction Confirmation Statements will be dispatched today, and quotation of the new shares is expected to commence tomorrow, 1 October 2008.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapeutics in the fields of brain injury, neurological diseases and conditions, and metabolic disorders including cancer. The Neuren portfolio comprises eight product families targeting markets with large unmet needs and limited competition. Neuren has three clinical-stage molecules — Glypromate[®], Motiva[™] and NNZ-2566 — focused on a range of acute and chronic neurological conditions as well as a discovery program targeting opportunities in the neurosciences and oncology. For more information visit www.neurenpharma.com.

For more information, contact:

Larry Glass, co-CEO Neuren (USA) T: +1 301 758 2987
Andrew Geddes, Seed Media T: +61 408 677 734